Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR): 10 pipeline candidates · 2 upcoming catalysts · ~11 mo cash runway · 14 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
10.9 months
D/E 0.26 · 0% dilution
Lead: Phase 3
10 candidates
2 upcoming, next in ~1778d
0 buys · 25 sells (180d)
A transparent, data-derived signal for Vir Biotechnology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.5B
Cash
$283.0M
Quarterly Burn
$132.4M
Runway
10.9 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| bulevirtide | Phase 3 |
| elebsiran | Phase 3 |
| peg-ifnα | Phase 2 |
| pegylated interferon-alfa 2a | Phase 2 |
| tobevibart | Phase 3 |
| vir-2218 | Phase 2 |
| vir-3434 | Phase 2 |
| vir-5500 | Phase 1 |
| vir-5525 | Phase 1 |
| vir-5818 | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
254
Total value held
$1.23B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 17,998,329 | $161.3M |
| arch venture management, llc | 12,916,663 | $115.7M |
| sb investment advisers (uk) ltd | 10,948,093 | $98.1M |
| vanguard capital management llc | 10,764,206 | $96.4M |
| vanguard portfolio management llc | 9,215,577 | $82.6M |
| state street corp | 7,141,094 | $64.0M |
| goldman sachs group inc | 3,250,227 | $29.1M |
| morgan stanley | 2,854,205 | $25.6M |
| adar1 capital management, llc | 2,744,714 | $24.6M |
| geode capital management, llc | 2,657,843 | $23.8M |
Showing top 10 of 254 institutional holders of Vir Biotechnology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Vir Biotechnology, Inc.'s pipeline?
Vir Biotechnology, Inc. (VIR) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vir Biotechnology, Inc.'s lead drug candidate?
Vir Biotechnology, Inc.'s most advanced tracked candidate is bulevirtide (Phase 3) for Viral Hepatitis.
What is Vir Biotechnology, Inc.'s next catalyst?
Vir Biotechnology, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran" — expected May 1, 2031.
What is Vir Biotechnology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vir Biotechnology, Inc. has approximately 10.9 months of cash runway.
What is Vir Biotechnology, Inc.'s market capitalization?
Vir Biotechnology, Inc.'s market capitalization is approximately $1.5B.
Get the full picture on Vir Biotechnology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.